ACON

Aclarion is a clinical-stage medical-technology company, not an operating business you can value on fundamentals. FY2025 revenue was $75.7K against a $7.23M net loss — an operating margin of -9,312% and a net margin of -9,552%. Five years of history confirm this is structural, not transitional: revenue has hovered between $45K and $76K since FY2021 while cumulative losses have driven the accumulated deficit to -$58.5M. Nociscan is a real, FDA-relevant SaaS diagnostic for low-back-pain discs, but the MD&A is explicit that commercial success hinges on securing payer coverage and converting temporary Category III CPT codes to permanent Category I codes — a reimbursement gate that has not been cleared and has no defined timeline.

The balance sheet looks superficially clean (liabilities/equity 0.07x, $12.0M cash, equity up 1,223% YoY), but that solvency was manufactured by financing, not operations: shares outstanding jumped 291.9% and the diluted EPS of -$13.61 against a $3.06 price signals a reverse split and relentless share issuance. Management states cash funds operations only through Q1 2028 and that it raised more via a registered direct offering after year-end — so the dilution the -$58.5M deficit records is ongoing, and existing holders are the funding source. Operating cash flow of -$7.16M means the $12M cash is roughly 1.7 years of runway before the next raise.